Lv3
252 积分 2025-05-06 加入
Second Malignancy Risks After Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: Differences by Lymphoma Subtype
34分钟前
待确认
Time-varying association of second primary malignancy and long-term survival outcomes in patients with head and neck cancer
1个月前
已完结
CAR T-cell therapy for secondary CNS DLBCL
3个月前
已完结
Early Use of Tocilizumab Following Cytokine Release Syndrome During CAR-T Therapy for Multiple Myeloma May Be Associated With Fewer Short and Long Term Adverse Cardiovascular Events
4个月前
已关闭
Clinical Outcomes in Relapsed DLBCL Patients Approved for CAR-T Therapy-A Single-Centre Study
5个月前
已完结
Impact of Baseline Anxiety and Depression on Toxicity and Outcomes after Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, and Tisangenleucel for Patients with Diffuse Large B-cell Lymphoma
5个月前
已完结
CLINICAL BIOMARKERS ASSOCIATED with PROGRESSION FREE SURVIVAL to CILTACABTAGENE AUTOLEUCEL in CHINESE PATIENTS with RELAPSED/REFRACTORY MULTIPLE MYELOMA from CARTIFAN-1 STUDY
5个月前
已关闭
皖公网安备34019202002308
